ArticleBJC reports2025
Bone marrow evaluation in neuroblastomas: bone marrow aspirates have little additional value over trephine biopsies.
Article in BJC reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone marrow involvement is essential for staging, treatment evaluation, and progression/relapse detection in neuroblastoma patients. We investigated the diagnostic accuracy of trephine biopsies (TBs) and the additional value of bone marrow aspirate (BMA) cytomorphology, considering clinical implications.
methodsData were collected from patients diagnosed at our centre over a seven-year period. Complete bone marrow evaluation (bilateral TBs and BMAs) was performed at diagnosis and at predefined timepoints. Cohen's kappa was used to compare test results. Representativeness was assessed for each TB and BMA and the presence or absence of tumour infiltration was reported.
resultsIn total, 197 neuroblastoma patients underwent bone marrow evaluation, yielding 1880 biopsies (947 procedures) and 1856 aspirates (934 procedures). TBs were representative in 94.9%, BMAs in 76.8% and complete bone marrow evaluation in 98.4%. Bone marrow infiltration was reported in 40.1%. TBs reported infiltration in 35.5% and BMAs in 19.7%. There was almost perfect agreement between TBs and complete evaluation (κ = 0.901, p < 0.001).
conclusionTBs showed higher sensitivity and representativity than BMA cytomorphology. In 4.6% of procedures, BMAs were positive while TBs were negative, but this never led to treatment alteration. These findings suggest that bilateral TBs alone may be sufficient to detect bone marrow involvement.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.